⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28875184 | 0.82 | HCAR2 (0.72) | — | |
| SCHEMBL2629428 | 0.80 | — | — | |
| SCHEMBL220072 | 0.80 | — | — | |
| SCHEMBL4420054 | 0.78 | — | — | |
| SCHEMBL3760634 | 0.78 | — | — | |
| SCHEMBL25678812 | 0.78 | HCAR2 (0.70) | — | |
| SCHEMBL16027471 | 0.78 | ALPL (0.61) | — | |
| SCHEMBL30078247 | 0.76 | HCAR2 (0.40) | — | |
| SCHEMBL159501 | 0.76 | — | — | |
| SCHEMBL159502 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | claimed |
| EP-4469461-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | Genase Therapeutics B.V. (NL) | 2024-12-04 | — | — | EP | claimed |
| CN-118001282-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-110997654-B | Indole derivatives and uses thereof | 诺华股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| WO-2023144332-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B.V. (NL) | 2023-08-03 | — | — | WO | claimed |
| CN-111094278-B | Diphenyl derivative and use thereof | 诺华股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| EP-2182950-B1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2017-07-19 | — | — | EP | claimed |
| EP-4469461-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | Genase Therapeutics B.V. (NL) | 2024-12-04 | — | — | EP | disclosed |
| CN-114466850-B | [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine | 拜耳股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118001282-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-110997654-B | Indole derivatives and uses thereof | 诺华股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023144332-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B.V. (NL) | 2023-08-03 | — | — | WO | disclosed |
| EP-1487828-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| EP-1478624-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003082861-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |